Literature DB >> 21394830

A mild neurofibromatosis type 1 phenotype produced by the combination of the benign nature of a leaky NF1-splice mutation and the presence of a complex mosaicism.

Juana Fernández-Rodríguez1, Joan Castellsagué, Llúcia Benito, Yolanda Benavente, Gabriel Capellá, Ignacio Blanco, Eduard Serra, Conxi Lázaro.   

Abstract

Here we analyze the genetic and molecular basis responsible for a very benign phenotype observed in an NF1 patient. Quantification of cells carrying the NF1 mutation in different samples derived from the three embryonic layers revealed mosaicism. Furthermore, the construction of a minigene with patient's mutation (c.3198 - 314G>A) confirmed its benign nature due to the leakiness of the splicing mechanism that generated a proportion of correctly spliced transcripts. Hence, we concluded that the mild phenotype observed in this patient is the result of the presence of mosaicism together with the benign nature of a leaky NF1-splice mutation. Finally, with the aim of developing a personalized therapeutic approach for this patient, we demonstrated correction of the splicing defect by using specific antisense morpholino oligomers. Our results provide an example of the molecular complexity behind disease phenotypes and highlight the importance of using comprehensive genetic approaches to better assess phenotype-genotype correlations.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21394830     DOI: 10.1002/humu.21500

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  8 in total

1.  The third international meeting on genetic disorders in the RAS/MAPK pathway: towards a therapeutic approach.

Authors:  Bruce Korf; Reza Ahmadian; Judith Allanson; Yoko Aoki; Annette Bakker; Emma Burkitt Wright; Brian Denger; Ype Elgersma; Bruce D Gelb; Karen W Gripp; Bronwyn Kerr; Maria Kontaridis; Conxi Lazaro; Corinne Linardic; Reymundo Lozano; Calum A MacRae; Ludwine Messiaen; Sonia Mulero-Navarro; Benjamin Neel; Scott Plotkin; Katherine A Rauen; Amy Roberts; Alcino J Silva; Sitta G Sittampalam; Chao Zhang; Lisa Schoyer
Journal:  Am J Med Genet A       Date:  2015-04-21       Impact factor: 2.802

Review 2.  Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.

Authors:  Kavitha Siva; Giuseppina Covello; Michela A Denti
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

Review 3.  Role of pseudoexons and pseudointrons in human cancer.

Authors:  Maurizio Romano; Emanuele Buratti; Diana Baralle
Journal:  Int J Cell Biol       Date:  2013-09-24

Review 4.  Mutation-Directed Therapeutics for Neurofibromatosis Type I.

Authors:  Andre Leier; David M Bedwell; Ann T Chen; George Dickson; Kim M Keeling; Robert A Kesterson; Bruce R Korf; Tatiana T Marquez Lago; Ulrich F Müller; Linda Popplewell; Jiangbing Zhou; Deeann Wallis
Journal:  Mol Ther Nucleic Acids       Date:  2020-04-29       Impact factor: 8.886

5.  AG-exclusion zone revisited: Lessons to learn from 91 intronic NF1 3' splice site mutations outside the canonical AG-dinucleotides.

Authors:  Katharina Wimmer; Esther Schamschula; Annekatrin Wernstedt; Pia Traunfellner; Albert Amberger; Johannes Zschocke; Peter Kroisel; Yunjia Chen; Tom Callens; Ludwine Messiaen
Journal:  Hum Mutat       Date:  2020-03-11       Impact factor: 4.878

6.  Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.

Authors:  Josep Biayna; Helena Mazuelas; Bernat Gel; Ernest Terribas; Gabrijela Dumbovic; Inma Rosas; Juana Fernández-Rodriguez; Ignacio Blanco; Elisabeth Castellanos; Meritxell Carrió; Conxi Lazaro; Eduard Serra
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

7.  Analysis of Pathogenic Pseudoexons Reveals Novel Mechanisms Driving Cryptic Splicing.

Authors:  Niall P Keegan; Steve D Wilton; Sue Fletcher
Journal:  Front Genet       Date:  2022-01-24       Impact factor: 4.772

8.  Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I.

Authors:  André Leier; Marc Moore; Hui Liu; Michael Daniel; Alexis M Hyde; Ludwine Messiaen; Bruce R Korf; Jamuna Selvakumaran; Lukasz Ciszewski; Laura Lambert; Jeremy Foote; Margaret R Wallace; Robert A Kesterson; George Dickson; Linda Popplewell; Deeann Wallis
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-15       Impact factor: 8.886

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.